A detailed history of Royal Bank Of Canada transactions in Xencor Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 7,513 shares of XNCR stock, worth $173,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,513
Previous 6,379 17.78%
Holding current value
$173,324
Previous $120,000 25.83%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.7 - $21.65 $17,803 - $24,551
1,134 Added 17.78%
7,513 $151,000
Q2 2024

Aug 14, 2024

BUY
$18.21 - $24.5 $80,306 - $108,045
4,410 Added 223.97%
6,379 $120,000
Q1 2024

Nov 05, 2024

SELL
$18.65 - $26.52 $82,246 - $116,953
-4,410 Reduced 69.13%
1,969 $43,000
Q1 2024

May 15, 2024

SELL
$18.65 - $26.52 $305,822 - $434,874
-16,398 Reduced 89.28%
1,969 $43,000
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $153,266 - $198,606
9,272 Added 101.95%
18,367 $389,000
Q3 2023

Nov 14, 2023

BUY
$20.08 - $25.39 $73,753 - $93,257
3,673 Added 67.74%
9,095 $183,000
Q2 2023

Aug 14, 2023

BUY
$24.77 - $29.9 $31,829 - $38,421
1,285 Added 31.06%
5,422 $135,000
Q1 2023

May 15, 2023

SELL
$25.95 - $36.95 $111,844 - $159,254
-4,310 Reduced 51.02%
4,137 $115,000
Q4 2022

Feb 14, 2023

BUY
$24.79 - $30.86 $167,803 - $208,891
6,769 Added 403.4%
8,447 $219,000
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $5,342 - $7,039
217 Added 14.85%
1,678 $44,000
Q2 2022

Aug 15, 2022

SELL
$19.74 - $29.01 $67,116 - $98,634
-3,400 Reduced 69.94%
1,461 $40,000
Q1 2022

May 16, 2022

SELL
$26.68 - $41.63 $205,409 - $320,509
-7,699 Reduced 61.3%
4,861 $130,000
Q4 2021

Feb 14, 2022

BUY
$33.67 - $43.44 $370,336 - $477,796
10,999 Added 704.61%
12,560 $503,000
Q3 2021

Nov 15, 2021

SELL
$30.65 - $35.68 $118,186 - $137,582
-3,856 Reduced 71.18%
1,561 $51,000
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $185,965 - $242,031
5,417 New
5,417 $187,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.38B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.